Trial Profile
A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Melphalan (Primary) ; Melphalan (Primary) ; Cyclophosphamide; Prednisone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms EMN02/HOVON 95; HO95
- 22 Nov 2023 This study has been completed in Austria, according to European Clinical Trials Database record.
- 17 Aug 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.
- 05 Feb 2022 Results from the NMSG flow-MRD substudy published in the BMC Cancer